DNA graphic

Search Results for: lupus nephritis

Lupus Research Alliance Hails Approval of Aurinia’s Lupkynis(TM) (voclosoporin)

First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month NEW YORK, NY. January 22, 2021. The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals’ LupkynisTM (voclosporin) as the first oral treatment developed specifically for […]

LRA Applauds Exciting Lupus Research Being Presented at 2019 ACR/ARP Annual Meeting

Includes 16 presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways Results from two clinical studies conducted by LRA-affiliate Lupus Therapeutics (LT) in collaboration with Rilite Foundation and Pfizer to be presented Extensive positive studies focused on lupus, including successful Phase 3 and Phase 2 clinical and mechanistic data […]

LuCIN Clinical Studies

The Lupus Clinical Investigators Network (LuCIN) is a North American-based lupus clinical trials network composed of fifty-seven (57) of the most reputable academic research medical centers in the world. LuCIN brings together the biopharmaceutical industry and lupus experts to evaluate the safety and effectiveness of new therapies for lupus. The investigators and other specialized personnel […]

Research Partners

Collaboration is one of the cornerstones of the Lupus Research Alliance’s research philosophy. We strive to identify and engage partners across disciplines and sectors to accelerate foundational and translational research in lupus. We welcome new partnering opportunities. Please contact Teodora Staeva, Ph.D. (tstaeva@lupusreserach.org)  

Lupus Research Alliance Announces New Grants For Translational Research

Jan. 10, 2018 Lupus Research Alliance Announces New Grants for Translational Research Seven Outstanding Investigators Chosen for Prestigious Lupus Research Grants The Lupus Research Alliance is proud to announce the recipients of its Target Identification in Lupus (TIL) grants designed to move research discoveries quickly from the laboratory to the patient’s bedside. Seven outstanding scientists […]

LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis

September 16, 2020 NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s New England Journal of Medicine, demonstrating that GSK’s drug Benlysta® (belimumab) significantly improved kidney function in adults with lupus nephritis, the most common severe complication of lupus causing inflammation and serious damage to the kidney. The […]

Our Progress

Advancing Scientific Breakthroughs to Date: Directly invested more than $220 million in the most promising lupus research Awarded more than 525 grants supporting innovative lupus research and accelerated the pace of discovery Supported research that has contributed to the identification or further validation of at least 15 different disease pathways in lupus and has enabled […]

New Survey Shows Education and Communication Gaps in Lupus Nephritis Care

1 in 2 Lupus Nephritis Patients Don’t Know They Have Lupus New York, NY– December 7, 2020.  Significant gaps in education and communication among patients and physicians pose barriers to lupus nephritis (LN) care, according to results of two companion surveys conducted by the National Kidney Foundation (NKF) and the Lupus Research Alliance (LRA). Half […]